A cost-effective innovation in anaemia management for paediatric patients with haemodialysis-dependent chronic kidney disease.

IF 2.6 3区 医学 Q1 PEDIATRICS
Pediatric Nephrology Pub Date : 2025-07-01 Epub Date: 2025-03-01 DOI:10.1007/s00467-025-06680-x
Rebecca Preston, Demetria Theodorou, Kate Sinnott, Dean Wallace, Amrit Kaur
{"title":"A cost-effective innovation in anaemia management for paediatric patients with haemodialysis-dependent chronic kidney disease.","authors":"Rebecca Preston, Demetria Theodorou, Kate Sinnott, Dean Wallace, Amrit Kaur","doi":"10.1007/s00467-025-06680-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Paediatric patients undergoing haemodialysis typically require intravenous (IV) iron therapy to replenish iron stores. Upon establishing our home haemodialysis service, the need for an efficient IV iron administration method prompted exploration beyond the conventional use of iron sucrose, which is associated with anaphylaxis and requires frequent infusions. Ferric carboxymaltose has a favourable safety profile and corrects iron deficiency with less frequent infusions. We aimed to establish if ferric carboxymaltose was a viable alternative in this patient group.</p><p><strong>Methods: </strong>This single-centre, uncontrolled retrospective cohort study assessed the effectiveness of ferric carboxymaltose in maintaining laboratory parameters (haemoglobin level, transferrin saturation and reticulocyte haemoglobin content) within target range in our home haemodialysis population. Secondly, we conducted a comparative analysis to establish maintenance efficacy of ferric carboxymaltose, versus iron sucrose over a 12-month period. Finally, we performed a cost-effectiveness analysis of IV iron therapy, considering cost per dose and per month of treatment.</p><p><strong>Results: </strong>Following ferric carboxymaltose infusion, we observed significant increases in haemoglobin level, transferrin saturation and reticulocyte haemoglobin content, which was maintained at 3-month post-infusion. Ferric carboxymaltose demonstrated comparable efficacy to iron sucrose in maintaining laboratory parameters. Strikingly, ferric carboxymaltose treatment was associated with significantly decreased number of infusions per month (~ tenfold) and a significant cost-saving (~ fivefold).</p><p><strong>Conclusions: </strong>This study underscores the clinical efficacy and economic benefits of ferric carboxymaltose as a viable treatment for iron deficiency anaemia in paediatric patients who are haemodialysis-dependent and highlights the potential for significant improvements in healthcare delivery, in terms of reducing frequency of hospital visits for this patient population.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"2353-2361"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116716/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00467-025-06680-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Paediatric patients undergoing haemodialysis typically require intravenous (IV) iron therapy to replenish iron stores. Upon establishing our home haemodialysis service, the need for an efficient IV iron administration method prompted exploration beyond the conventional use of iron sucrose, which is associated with anaphylaxis and requires frequent infusions. Ferric carboxymaltose has a favourable safety profile and corrects iron deficiency with less frequent infusions. We aimed to establish if ferric carboxymaltose was a viable alternative in this patient group.

Methods: This single-centre, uncontrolled retrospective cohort study assessed the effectiveness of ferric carboxymaltose in maintaining laboratory parameters (haemoglobin level, transferrin saturation and reticulocyte haemoglobin content) within target range in our home haemodialysis population. Secondly, we conducted a comparative analysis to establish maintenance efficacy of ferric carboxymaltose, versus iron sucrose over a 12-month period. Finally, we performed a cost-effectiveness analysis of IV iron therapy, considering cost per dose and per month of treatment.

Results: Following ferric carboxymaltose infusion, we observed significant increases in haemoglobin level, transferrin saturation and reticulocyte haemoglobin content, which was maintained at 3-month post-infusion. Ferric carboxymaltose demonstrated comparable efficacy to iron sucrose in maintaining laboratory parameters. Strikingly, ferric carboxymaltose treatment was associated with significantly decreased number of infusions per month (~ tenfold) and a significant cost-saving (~ fivefold).

Conclusions: This study underscores the clinical efficacy and economic benefits of ferric carboxymaltose as a viable treatment for iron deficiency anaemia in paediatric patients who are haemodialysis-dependent and highlights the potential for significant improvements in healthcare delivery, in terms of reducing frequency of hospital visits for this patient population.

血液透析依赖性慢性肾病患儿贫血管理的成本效益创新。
背景:接受血液透析的儿科患者通常需要静脉(IV)铁治疗来补充铁储备。在建立我们的家庭血液透析服务后,对一种有效的静脉给铁方法的需求促使我们探索超越常规使用蔗糖铁的方法,蔗糖铁与过敏反应有关,需要经常输注。羧麦芽糖铁具有良好的安全性和纠正缺铁较少频繁的输液。我们的目的是确定是否铁羧基麦芽糖是一个可行的替代品,在这个病人组。方法:这项单中心、无控制的回顾性队列研究评估了羧麦芽糖铁在我们的家庭血液透析人群中维持实验室参数(血红蛋白水平、转铁蛋白饱和度和网状红细胞血红蛋白含量)在目标范围内的有效性。其次,我们进行了比较分析,以确定在12个月的时间内,三羧基麦芽糖铁与蔗糖铁的维持功效。最后,我们进行了IV铁治疗的成本-效果分析,考虑了每剂量和每月治疗的成本。结果:在三铁羧麦芽糖输注后,我们观察到血红蛋白水平、转铁蛋白饱和度和网状红细胞血红蛋白含量显著增加,并维持在输注后3个月。羧基麦芽糖铁在维持实验室参数方面表现出与蔗糖铁相当的功效。引人注目的是,羧基麦芽糖铁治疗与每月输液次数显著减少(约10倍)和显著节省成本(约5倍)相关。结论:本研究强调了羧基麦芽糖铁作为血液透析依赖的儿童缺铁性贫血患者的一种可行治疗方法的临床疗效和经济效益,并强调了在减少这类患者就诊频率方面,医疗保健服务的显著改善潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pediatric Nephrology
Pediatric Nephrology 医学-泌尿学与肾脏学
CiteScore
4.70
自引率
20.00%
发文量
465
审稿时长
1 months
期刊介绍: International Pediatric Nephrology Association Pediatric Nephrology publishes original clinical research related to acute and chronic diseases that affect renal function, blood pressure, and fluid and electrolyte disorders in children. Studies may involve medical, surgical, nutritional, physiologic, biochemical, genetic, pathologic or immunologic aspects of disease, imaging techniques or consequences of acute or chronic kidney disease. There are 12 issues per year that contain Editorial Commentaries, Reviews, Educational Reviews, Original Articles, Brief Reports, Rapid Communications, Clinical Quizzes, and Letters to the Editors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信